Roche and Genen­tech's lat­est AI col­lab­o­ra­tor rais­es $25M Se­ries A to rein­vent one of the old­est can­cer tar­gets

Jon­ah Kallen­bach spent the sum­mer be­fore his se­nior year with An­ton, the hulk­ing flu­o­res­cent su­per­com­put­er housed in the mid­town Man­hat­tan of­fices of hedge fund D.E. Shaw. Armed with 512 proces­sors run­ning in par­al­lel, it’s been used since 2008 to probe some of the biggest ques­tions in pro­tein fold­ing and struc­ture.

Kallen­bach can’t talk much about what he worked on, but he was hooked, and af­ter his last year at Har­vard, he want­ed to go in­to drug de­vel­op­ment. But when he went look­ing for phar­ma roles, he found few of the com­pa­nies had space for com­pu­ta­tion­als. Or they had space, but that space was small and cor­doned off from the rest of a mas­sive or­ga­ni­za­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER